Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
Tvt2c6KvXCb3FWG8
